{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:03:44Z","timestamp":1781273024612,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,9]],"date-time":"2027-04-09T00:00:00Z","timestamp":1807228800000},"content-version":"am","delay-in-days":282,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA241823"],"award-info":[{"award-number":["CA241823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118803","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:21:03Z","timestamp":1774815663000},"page":"118803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging"],"prefix":"10.1016","volume":"311","author":[{"given":"Atchimnaidu","family":"Siriki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ragland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-2286","authenticated-orcid":false,"given":"Satish K.","family":"Chitneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118803_bib1","first-page":"6304","article-title":"Participation of p53 protein in the cellular response to DNA damage","volume":"51","author":"Kastan","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118803_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2026.118803_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.118803_bib5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118803_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.onc.1201432","article-title":"Mdm2: keeping p53 under control","volume":"15","author":"Piette","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118803_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein","volume":"55","author":"Freedman","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.118803_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jmcb\/mjx007","article-title":"The role of MDM2 and MDM4 in breast cancer development and prevention","volume":"9","author":"Haupt","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118803_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.1.2.1","article-title":"MDM2 and prognosis","volume":"2","author":"Onel","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118803_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s10147-013-0639-1","article-title":"Subcellular localization of Mdm2 expression and prognosis of breast cancer","volume":"19","author":"Park","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib12","doi-asserted-by":"crossref","first-page":"15608","DOI":"10.1073\/pnas.95.26.15608","article-title":"Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis","volume":"95","author":"Jones","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118803_bib13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2026.118803_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1006959","article-title":"Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma","volume":"12","author":"Traweek","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.onc.1201646","article-title":"High prognostic significance of Mdm2\/p53 co-overexpression in soft tissue sarcomas of the extremities","volume":"16","author":"Wurl","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118803_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1006410702284","article-title":"Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors","volume":"49","author":"Schiebe","year":"2000","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/modpathol.3800484","article-title":"MDM2 protein expression is a negative prognostic marker in breast carcinoma","volume":"19","author":"Turbin","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejmech.2026.118803_bib18","first-page":"16","article-title":"Therapeutic strategies to activate p53","author":"Aguilar","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118803_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118803_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130394","article-title":"A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT","volume":"129","author":"Siriki","year":"2025","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118803_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib22","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","article-title":"Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","volume":"101","author":"Reis","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.118803_bib23","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0901","article-title":"BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed\/refractory myelofibrosis","author":"Verstovsek","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-0762","article-title":"Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results","author":"Dumbrava","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2017.03.013","article-title":"Reviving the guardian of the genome: small molecule activators of p53","volume":"178","author":"Nguyen","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118803_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118803_bib27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib28","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2026.118803_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib30","first-page":"1306","article-title":"Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics","volume":"6","author":"Kimura","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2026.118803_bib31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12105-020-01139-x","article-title":"The utility of MDM2 and CDK4 immunohistochemistry and MDM2 FISH in craniofacial osteosarcoma","volume":"14","author":"Limbach","year":"2020","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.ejmech.2026.118803_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/812089","article-title":"Fluorescence in situ hybridization for MDM2 amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: experience at a tertiary center","volume":"2015","author":"Thway","year":"2015","journal-title":"Sarcoma"},{"key":"10.1016\/j.ejmech.2026.118803_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040358","article-title":"Feasibility of developing radiotracers for MDM2: synthesis and preliminary evaluation of an 18F-Labeled Analogue oa the MDM2 Inhibitor iP-141","volume":"14","author":"Chitneni","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118803_bib34","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1021\/acs.molpharmaceut.1c00531","article-title":"Fluorine-18 labeling of the MDM2 inhibitor RG7388 for PET imaging: chemistry and preliminary evaluation","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.118803_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128725","article-title":"Stapled peptides as scaffolds for developing radiotracers for intracellular targets: preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model","volume":"66","author":"Zhou","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118803_bib36","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1016\/j.tetlet.2007.08.030","article-title":"A simple method for chemoselective phenol alkylation","volume":"48","author":"Liu","year":"2007","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2026.118803_bib37","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118803_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jnci\/86.17.1297","article-title":"Mdm2 gene amplification and transcript levels in human sarcomas - relationship to Tp53 gene status","volume":"86","author":"Florenes","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"issue":"211","key":"10.1016\/j.ejmech.2026.118803_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1471-2407-11-211","article-title":"MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines","volume":"11","author":"Ohnstad","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.118803_bib40","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1021\/acs.bioconjchem.8b00315","article-title":"Highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition","volume":"29","author":"Lebraud","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.118803_bib41","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.bmc.2014.05.072","article-title":"Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118803_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"MDM2-Recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118803_bib43","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/ejoc.201801457","article-title":"Convenient entry to 18F-Labeled Amines thraugh the StaudingersReduction","volume":"2019","author":"St\u00e9en","year":"2019","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2026.118803_bib44","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1039\/C7OB00880E","article-title":"[18F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry","volume":"15","author":"Denk","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118803_bib45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET imaging of PARP expression using 18F-Olaparib","volume":"60","author":"Wilson","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.118803_bib46","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2967\/jnumed.110.077982","article-title":"Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts","volume":"51","author":"Fu","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.118803_bib47","doi-asserted-by":"crossref","first-page":"23389","DOI":"10.1021\/acs.jmedchem.5c02183","article-title":"64Cu-Labeled stapled peptide-based radiopharmaceuticals targeting MDM2\/MDMX for Pan-p53 tumors","volume":"68","author":"Tian","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:47:41Z","timestamp":1781272061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"alternative-id":["S0223523426002485"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118803","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118803"}}